Kolhe Lab
Ravindra Kolhe, MD, PhD, FCAP
Professor and Chair, Department of Pathology
Edgar R. Pund, MD, Distinguished Chair in Pathology
Director, Georgia Esoteric and Molecular Laboratory
Associate Dean for Translational Research, Medical College of Georgia
Associate Director for Genomics, Georgia Cancer Center
Ravindra Kolhe is a Professor and Distinguished Chair of Pathology at the Medical College of Georgia at Augusta University and is the inaugural Associate Dean for Translation Research at Medical College of Georgia. He also serves as the Associate Director for Genomics at the Georgia Cancer Center.
Currently, Dr. Kolhe leads an NCI-designated translational pathology laboratory for MATCH (Molecular Analysis for Therapy Choice) comprehensive genomic testing in oncology. He co-founded a consortium (SEQUOIA) of over 40+ clinical laboratories across the globe for the democratization of NGS testing in oncology and successfully helped multiple labs bring NGS testing in-house. He has led several studies focused on adapting and validating newer technologies (NGS, RNA-seq, OGM, etc.) in CLIA laboratories by establishing PLA, Z-codes, GAP filing, and reimbursement.
He has authored more than 100 peer-reviewed publications and serves on CAP committees and scientific advisory boards for numerous private and non-profit organizations.
Lab Members
Ashis Mondal, PhD
Lab Supervisor
Assistant Professor
Kimya Jones, MS, HT(ASCP)CM, QIHC(ASCP)CM
Lab Manager
Vishakha Vashisht, PhD
Postdoctoral Fellow
Pankaj Ahluwalia, PhD
Assistant Professor
Harmanpreet Singh, PhD
Research Associate
Ashutosh Vashisht, PhD
Postdoctoral Fellow
Jana Woodall, MPH
Pandemic Medicine Fellow
Data Coordinator TBD
Research Projects
SARS2 Seroprevalence and Respiratory Tract Assessment (SPARTA)
The goal of this project is to understand the immune responses that emerge in response to this Sars-COV-2 infection in health care workers and their immediate families.
Understanding the role of JAK inhibition (with Ruxolitinib) on the Donor T-cell population
The goal of this project is to investigate by pulsing donor cells with Ruxolitinib in the presence or absence of G-CSF, donor cells do not cause GVHD or cause only minor GVHD after transplantation.
Shaping the future of hereditary cancer testing in minorities
The major goal is to sequence 86 hereditary cancer genes on paired tumor/blood (germline) samples of all patients with solid tumors who undergo their surgery at AU Medical Center. While universal paired testing of tumor and blood (germline) provides direct clinical value to patients, we propose to study whether we can define and overcome minority barriers among Georgia Cancer Center patients.
Clinical validation of Saphyr technology for the identification of constitutional genomic variants in a pediatric neurodevelopmental cohort.
The goal of this study is to determine the performance of optical genome mapping as it compares to results from a standard of care genetic testing by chromosomal microarray, or karyotyping, or FISH. Concordance of results will be documented and analyzed in a pediatric neurodevelopmental cohort.
Validation of optical genome mapping (OGM) technology for the identification of constitutional genomic variants in a multisite prenatal study.
The goal of this study is to determine the performance of optical genome mapping as it compares to results from a standard of care genetic testing by chromosomal microarray, karyotyping or FISH. Concordance of results will be documented and analyzed in prenatal cases.
Cellular Heterogeneity and Tumor Microenvironment in Triple-Negative Breast Cancer Disparities
The goal of this project is to develop innovative therapeutic strategies targeting tumor cells and the tumor microenvironment (TME) in triple-negative breast cancer (TNBC), which disproportionally affects African American and other minority populations. We hypothesize that differential cellular subpopulations comprising tumor cells and the TME may contribute to disparate TNBC prevalence and treatment outcomes.
Clinical validation of Optical Genome Mapping for the identification of somatic genomic variants in hematological malignancies.
The goal of this study is to determine the performance of optical genome mapping as it compares to results from a standard of care genetic testing by chromosomal microarray, karyotyping or FISH in hematological malignancies.
